A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds


Cite item

Full Text

Abstract

:Cancers are a huge threat to human life and health. Every year, many people suffer and die from various cancers, and numerous resources have been used to combat cancer. Due to several disadvantages of anticancer agents, such as drug-induced side effects, drug resistance, etc., there are still wide gaps in their ability to conquer cancer. Therefore, there is an urgent need to discover and develop many novel chemotypes to suppress cancer. In this review, we mainly focus on the anticancer potency of two representative sorts of carbazole-based compounds: carboline derivatives and diazacarbazole derivatives. Diazacarbazole derivatives, which have not been fully explored yet, might bring us a new vision and a valuable opportunity for overcoming the enormous hurdle we are now facing in the cancer campaign. We also provide several synthetic approaches for constructing the critical skeletons of the carbazole-based tricyclic compounds.

About the authors

Hua Zhang

Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology

Email: info@benthamscience.net

Wen Zhang

Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology

Author for correspondence.
Email: info@benthamscience.net

Mengyu Zhu

ab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology

Email: info@benthamscience.net

Annoor Awadasseid

Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology

Email: info@benthamscience.net

References

  1. Kumar, S.; Singh, A.; Kumar, K.; Kumar, V. Recent insights into synthetic β-carbolines with anti-cancer activities. Eur. J. Med. Chem., 2017, 142, 48-73. doi: 10.1016/j.ejmech.2017.05.059 PMID: 28583770
  2. World Health Organization Report. Available from: http:/www.who.int/cancer/en/
  3. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLobocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  4. Petignat, P.; du Bois, A.; Bruchim, I.; Fink, D.; Provencher, D.M. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? Crit. Rev. Oncol. Hematol., 2007, 62(2), 137-147. doi: 10.1016/j.critrevonc.2006.11.009 PMID: 17188887
  5. Nicolson, M.; Leonard, R.C.F. Adverse effects of cancer chemotherapy. An overview of techniques for avoidance/minimisation. Drug Saf., 1992, 7(5), 316-322. doi: 10.2165/00002018-199207050-00002 PMID: 1418691
  6. Bukowski, K.; Kciuk, M.; Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci., 2020, 21(9), 3233. doi: 10.3390/ijms21093233 PMID: 32370233
  7. Phour, A.; Gaur, V.; Banerjee, A.; Bhattacharyya, J. Recombinant protein polymers as carriers of chemotherapeutic agents. Adv. Drug Deliv. Rev., 2022, 190, 114544. doi: 10.1016/j.addr.2022.114544 PMID: 36176240
  8. Schirrmacher, V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int. J. Oncol., 2018, 54(2), 407-419. doi: 10.3892/ijo.2018.4661 PMID: 30570109
  9. Hussain, M.; Gadgeel, S.; Kucuk, O.; Du, W.; Salwen, W.; Ensley, J. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer, 1999, 86(11), 2364-2369. doi: 10.1002/(SICI)1097-0142(19991201)86:113.0.CO;2-3 PMID: 10590379
  10. Abu Samaan, T.M.; Samec, M.; Liskova, A.; Kubatka, P.; Büsselberg, D. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules, 2019, 9(12), 789. doi: 10.3390/biom9120789 PMID: 31783552
  11. Gornstein, E.L.; Schwarz, T.L. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp. Neurol., 2017, 288, 153-166. doi: 10.1016/j.expneurol.2016.11.015 PMID: 27894788
  12. Du, X.; Khan, A.R.; Fu, M.; Ji, J.; Yu, A.; Zhai, G. Current development in the formulations of non-injection administration of paclitaxel. Int. J. Pharm., 2018, 542(1-2), 242-252. doi: 10.1016/j.ijpharm.2018.03.030 PMID: 29555439
  13. Thomas, A.C.G. Neurological adverse effects of cancer chemotherapy. Adverse Drug React. Bull., 2013, 278(1), 1071-1074. doi: 10.1097/FAD.0b013e32835ed7b5
  14. Wu, Q.; Yang, Z.; Nie, Y.; Shi, Y.; Fan, D. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett., 2014, 347(2), 159-166. doi: 10.1016/j.canlet.2014.03.013 PMID: 24657660
  15. Assaraf, Y.G.; Brozovic, A.; Gonçalves, A.C.; Jurkovicova, D.; Linē, A.; Machuqueiro, M.; Saponara, S.; Sarmento-Ribeiro, A.B.; Xavier, C.P.R.; Vasconcelos, M.H. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist. Updat., 2019, 46, 100645. doi: 10.1016/j.drup.2019.100645 PMID: 31585396
  16. Cegielski, J.P.; Dalton, T.; Yagui, M.; Wattanaamornkiet, W.; Volchenkov, G.V.; Via, L.E.; Van Der Walt, M.; Tupasi, T.; Smith, S.E.; Odendaal, R.; Leimane, V.; Kvasnovsky, C.; Kuznetsova, T.; Kurbatova, E.; Kummik, T.; Kuksa, L.; Kliiman, K.; Kiryanova, E.V.; Kim, H.; Kim, C.; Kazennyy, B.Y.; Jou, R.; Huang, W.L.; Ershova, J.; Erokhin, V.V.; Diem, L.; Contreras, C.; Cho, S.N.; Chernousova, L.N.; Chen, M.P.; Caoili, J.C.; Bayona, J.; Akksilp, S.; Calahuanca, G.Y.; Wolfgang, M.; Viiklepp, P.; Vasilieva, I.A.; Taylor, A.; Tan, K.; Suarez, C.; Sture, I.; Somova, T.; Smirnova, T.G.; Sigman, E.; Skenders, G.; Sitti, W.; Shamputa, I.C.; Riekstina, V.; Pua, K.R.; Therese, M.; Perez, C.; Park, S.; Norvaisha, I.; Nemtsova, E.S.; Min, S.; Metchock, B.; Levina, K.; Lei, Y-C.; Lee, J.; Larionova, E.E.; Lancaster, J.; Jeon, D.; Jave, O.; Khorosheva, T.; Hwang, S.H.; Huang, A.S-E.; Gler, M.T.; Dravniece, G.; Eum, S.; Demikhova, O.V.; Degtyareva, I.; Danilovits, M.; Cirula, A.; Cho, E.; Cai, Y.; Brand, J.; Bonilla, C.; Barry, C.E.; Asencios, L.; Andreevskaya, S.N.; Akksilp, R. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis., 2014, 59(8), 1049-1063. doi: 10.1093/cid/ciu572 PMID: 25057101
  17. Stavrovskaya, A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry. Biokhimiia, 2000, 65(1), 95-106.
  18. Catalano, A.; Iacopetta, D.; Ceramella, J.; Scumaci, D.; Giuzio, F.; Saturnino, C.; Aquaro, S.; Rosano, C.; Sinicropi, M.S. Multidrug Resistance (MDR): A widespread phenomenon in pharmacological therapies. Molecules, 2022, 27(3), 616. doi: 10.3390/molecules27030616 PMID: 35163878
  19. Yang, X.; Liu, K. P-gp inhibition-based strategies for modulating pharmacokinetics of anticancer drugs: An update. Curr. Drug Metab., 2016, 17(8), 806-826. doi: 10.2174/1389200217666160629112717 PMID: 27364832
  20. Ling, V. P-glycoprotein: Its role in drug resistance. Am. J. Med., 1995, 99(6), 31s-34s. doi: 10.1016/S0002-9343(99)80283-6 PMID: 8585532
  21. Mollazadeh, S.; Sahebkar, A.; Hadizadeh, F.; Behravan, J.; Arabzadeh, S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci., 2018, 214, 118-123. doi: 10.1016/j.lfs.2018.10.048 PMID: 30449449
  22. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures; Springer: Dordrecht, 2011.
  23. Tomar, M.S.; Kumar, A.; Srivastava, C.; Shrivastava, A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim. Biophys. Acta Rev. Cancer, 2021, 1876(2), 188616. doi: 10.1016/j.bbcan.2021.188616 PMID: 34419533
  24. Pommier, Y.; Pharm, D.; Fesen, M.R.; Fujimori, A.; Bertrand, R.; Solary, E.; Kohlhagen, G.; Kohn, K.W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 1994, 12(5), 530-542. doi: 10.3109/07357909409021413 PMID: 7922710
  25. Robert, J.; Larsen, A.K. Drug resistance to topoisomerase II inhibitors. Biochimie, 1998, 80(3), 247-254. doi: 10.1016/S0300-9084(98)80007-2 PMID: 9615864
  26. Casorelli, I.; Bossa, C.; Bignami, M. DNA damage and repair in human cancer: Molecular mechanisms and contribution to therapy-related leukemias. Int. J. Environ. Res. Public Health, 2012, 9(8), 2636-2657. doi: 10.3390/ijerph9082636 PMID: 23066388
  27. Wray, J.; Williamson, E.A.; Sheema, S.; Lee, S.H.; Libby, E.; Willman, C.L.; Nickoloff, J.A.; Hromas, R. Metnase mediates chromosome decatenation in acute leukemia cells. Blood, 2009, 114(9), 1852-1858. doi: 10.1182/blood-2008-08-175760 PMID: 19458360
  28. Wray, J.; Williamson, E.A.; Royce, M.; Shaheen, M.; Beck, B.D.; Lee, S.H.; Nickoloff, J.A.; Hromas, R. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS One, 2009, 4(4), e5323. doi: 10.1371/journal.pone.0005323 PMID: 19390626
  29. Costantino, L.; Barlocco, D. Designed multiple ligands: Basic research vs clinical outcomes. Curr. Med. Chem., 2012, 19(20), 3353-3387. doi: 10.2174/092986712801215883 PMID: 22680630
  30. Swinney, D.C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov., 2011, 10(7), 507-519. doi: 10.1038/nrd3480 PMID: 21701501
  31. Kucuksayan, E.; Ozben, T. Hybrid compounds as multitarget directed anticancer agents. Curr. Top. Med. Chem., 2017, 17(8), 907-918. doi: 10.2174/1568026616666160927155515 PMID: 27697050
  32. Oliveira Pedrosa, M.; Duarte da Cruz, R.; Oliveira Viana, J.; de Moura, R.; Ishiki, H.; Barbosa Filho, J.; Diniz, M.; Scotti, M.; Scotti, L.; Bezerra Mendonca, F. Hybrid compounds as direct multitarget ligands: A review. Curr. Top. Med. Chem., 2017, 17(9), 1044-1079. doi: 10.2174/1568026616666160927160620 PMID: 27697048
  33. Alam, M.M.; Hassan, A.H.E.; Kwon, Y.H.; Lee, H.J.; Kim, N.Y.; Min, K.H.; Lee, S.Y.; Kim, D.H.; Lee, Y.S. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents. Arch. Pharm. Res., 2018, 41(1), 35-45. doi: 10.1007/s12272-017-0977-z PMID: 29094267
  34. Chen, Z.; Han, L.; Xu, M.; Xu, Y.; Qian, X. Rationally designed multitarget anticancer agents. Curr. Med. Chem., 2013, 20(13), 1694-1714. doi: 10.2174/0929867311320130009 PMID: 23410168
  35. Xi, J.J.; He, R.Y.; Zhang, J.K.; Cai, Z.B.; Zhuang, R.X.; Zhao, Y.M.; Shao, Y.D.; Pan, X.W.; Shi, T.T.; Dong, Z.J.; Liu, S.R.; Kong, L.M. Design, synthesis, and biological evaluation of novel 3-(thiophen-2-ylthio)pyridine derivatives as potential multitarget anticancer agents. Arch. Pharm., 2019, 352(8), 1900024. doi: 10.1002/ardp.201900024 PMID: 31338897
  36. Zhang, L.; Shan, Y.; Ji, X.; Zhu, M.; Li, C.; Sun, Y.; Si, R.; Pan, X.; Wang, J.; Ma, W.; Dai, B.; Wang, B.; Zhang, J. Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents. Oncotarget, 2017, 8(62), 104745-104760. doi: 10.18632/oncotarget.20065 PMID: 29285210
  37. Wang, J.; Zhang, L.; Pan, X.; Dai, B.; Sun, Y.; Li, C.; Zhang, J. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents. Sci. Rep., 2017, 7(1), 45145. doi: 10.1038/srep45145 PMID: 28332573
  38. Kaise, A.; Ohta, K.; Endo, Y. Novel p-carborane-containing multitarget anticancer agents inspired by the metabolism of 17β-estradiol. Bioorg. Med. Chem., 2017, 25(24), 6371-6378. doi: 10.1016/j.bmc.2017.10.006 PMID: 29054710
  39. Gu, W.; Wang, S. Synthesis and antimicrobial activities of novel 1H-dibenzoa,ccarbazoles from dehydroabietic acid. Eur. J. Med. Chem., 2010, 45(10), 4692-4696. doi: 10.1016/j.ejmech.2010.07.038 PMID: 20702006
  40. Yaqub, G.; Hannan, A.; Akbar, E.; Usman, M.; Hamid, A.; Sadiq, Z.; Iqbal, M. Synthesis, antibacterial, and antifungal activities of novel pyridazino carbazoles. J. Chem., 2013, 2013, 1-7. doi: 10.1155/2013/818739
  41. Zhang, F.F.; Gan, L.L.; Zhou, C.H. Synthesis, antibacterial and antifungal activities of some carbazole derivatives. Bioorg. Med. Chem. Lett., 2010, 20(6), 1881-1884. doi: 10.1016/j.bmcl.2010.01.159 PMID: 20176480
  42. Gu, W.; Qiao, C.; Wang, S.F.; Hao, Y.; Miao, T.T. Synthesis and biological evaluation of novel N-substituted 1H-dibenzoa,ccarbazole derivatives of dehydroabietic acid as potential antimicrobial agents. Bioorg. Med. Chem. Lett., 2014, 24(1), 328-331. doi: 10.1016/j.bmcl.2013.11.009 PMID: 24300736
  43. Bandgar, B.P.; Adsul, L.K.; Chavan, H.V.; Jalde, S.S.; Shringare, S.N.; Shaikh, R.; Meshram, R.J.; Gacche, R.N.; Masand, V. Synthesis, biological evaluation, and docking studies of 3-(substituted)-aryl-5-(9-methyl-3-carbazole)-1H-2-pyrazolines as potent anti-inflammatory and antioxidant agents. Bioorg. Med. Chem. Lett., 2012, 22(18), 5839-5844. doi: 10.1016/j.bmcl.2012.07.080 PMID: 22901385
  44. Bashir, M.; Bano, A.; Ijaz, A.; Chaudhary, B. Recent developments and biological activities of n-substituted carbazole derivatives: A review. Molecules, 2015, 20(8), 13496-13517. doi: 10.3390/molecules200813496 PMID: 26213906
  45. Tsutsumi, L.S.; Gündisch, D.; Sun, D. Carbazole scaffold in medicinal chemistry and natural products: A review from 2010-2015. Curr. Top. Med. Chem., 2016, 16(11), 1290-1313. doi: 10.2174/1568026615666150915112647 PMID: 26369811
  46. Cao, R.; Peng, W.; Wang, Z.; Xu, A. beta-Carboline alkaloids: biochemical and pharmacological functions. Curr. Med. Chem., 2007, 14(4), 479-500. doi: 10.2174/092986707779940998 PMID: 17305548
  47. Mineno, M.; Sera, M.; Ueda, T.; Mizufune, H.; Zanka, A.; O’Bryan, C.; Brown, J.; Scorah, N. Integrated cross-coupling strategy for an α-carboline-based Aurora B kinase inhibitor. J. Org. Chem., 2015, 80(3), 1564-1568. doi: 10.1021/jo502489x PMID: 25616084
  48. Chauhan, S.S.; Singh, A.K.; Meena, S.; Lohani, M.; Singh, A.; Arya, R.K.; Cheruvu, S.H.; Sarkar, J.; Gayen, J.R.; Datta, D.; Chauhan, P.M.S. Synthesis of novel β-carboline based chalcones with high cytotoxic activity against breast cancer cells. Bioorg. Med. Chem. Lett., 2014, 24(13), 2820-2824. doi: 10.1016/j.bmcl.2014.04.109 PMID: 24844196
  49. Lim, J.; Taoka, B.; Otte, R.D.; Spencer, K.; Dinsmore, C.J.; Altman, M.D.; Chan, G.; Rosenstein, C.; Sharma, S.; Su, H.P.; Szewczak, A.A.; Xu, L.; Yin, H.; Zugay-Murphy, J.; Marshall, C.G.; Young, J.R. Discovery of 1-amino-5H-pyrido4,3-bindol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. J. Med. Chem., 2011, 54(20), 7334-7349. doi: 10.1021/jm200909u PMID: 21942426
  50. Abboud, M.; Aubert, E.; Mamane, V. Double N-arylation reaction of polyhalogenated 4,4′-bipyridines. Expedious synthesis of functionalized 2,7-diazacarbazoles. Beilstein J. Org. Chem., 2012, 8, 253-258. doi: 10.3762/bjoc.8.26 PMID: 22423292
  51. Abboud, M.; Mamane, V.; Aubert, E.; Lecomte, C.; Fort, Y. Synthesis of polyhalogenated 4,4′-bipyridines via a simple dimerization procedure. J. Org. Chem., 2010, 75(10), 3224-3231. doi: 10.1021/jo100152e PMID: 20426403
  52. Joan, D.H.; J, G.l.; Karen, W. 1,7-Diazacarbazoles and their use in the treatment of cancer. WO Patent 073263, 2011.
  53. Alekseyev, R.S.; Kurkin, A.V.; Yurovskaya, M.A. The Piloty-Robinson reaction of N-substituted piperidin-4-one azines. A novel route for the synthesis of 3,6-diazacarbazole. Chem. Heterocycl. Compd., 2011, 47(5), 584-596. doi: 10.1007/s10593-011-0802-4
  54. Lunagariya, N.A.; Gohil, V.M.; Kushwah, V.; Neelagiri, S.; Jain, S.; Singh, S.; Bhutani, K.K. Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential. Bioorg. Med. Chem. Lett., 2016, 26(3), 789-794. doi: 10.1016/j.bmcl.2015.12.095 PMID: 26791014
  55. Kamal, A.; Narasimha Rao, M.P.; Swapna, P.; Srinivasulu, V.; Bagul, C.; Shaik, A.B.; Mullagiri, K.; Kovvuri, J.; Reddy, V.S.; Vidyasagar, K.; Nagesh, N. Synthesis of β-carboline–benzimidazole conjugates using lanthanum nitrate as a catalyst and their biological evaluation. Org. Biomol. Chem., 2014, 12(15), 2370-2387. doi: 10.1039/C3OB42236D PMID: 24604306
  56. Kovvuri, J.; Nagaraju, B.; Nayak, V.L.; Akunuri, R.; Rao, M.P.N.; Ajitha, A.; Nagesh, N.; Kamal, A. Design, synthesis and biological evaluation of new β-carboline-bisindole compounds as DNA binding, photocleavage agents and topoisomerase I inhibitors. Eur. J. Med. Chem., 2018, 143, 1563-1577. doi: 10.1016/j.ejmech.2017.10.054 PMID: 29129513
  57. Sathish, M.; Kavitha, B.; Nayak, V.L.; Tangella, Y.; Ajitha, A.; Nekkanti, S.; Alarifi, A.; Shankaraiah, N.; Nagesh, N.; Kamal, A. Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors. Eur. J. Med. Chem., 2018, 144, 557-571. doi: 10.1016/j.ejmech.2017.12.055 PMID: 29289881
  58. Shankaraiah, N.; Siraj, K.P.; Nekkanti, S.; Srinivasulu, V.; Sharma, P.; Senwar, K.R.; Sathish, M.; Vishnuvardhan, M.V.P.S.; Ramakrishna, S.; Jadala, C.; Nagesh, N.; Kamal, A. DNA-binding affinity and anticancer activity of β-carboline–chalcone conjugates as potential DNA intercalators: Molecular modelling and synthesis. Bioorg. Chem., 2015, 59, 130-139. doi: 10.1016/j.bioorg.2015.02.007 PMID: 25771335
  59. Kamal, A.; Sathish, M.; Nayak, V.L.; Srinivasulu, V.; Kavitha, B.; Tangella, Y.; Thummuri, D.; Bagul, C.; Shankaraiah, N.; Nagesh, N. Design and synthesis of dithiocarbamate linked β-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability. Bioorg. Med. Chem., 2015, 23(17), 5511-5526. doi: 10.1016/j.bmc.2015.07.037 PMID: 26264845
  60. Shuai, K.; Liu, B. Regulation of JAK–STAT signalling in the immune system. Nat. Rev. Immunol., 2003, 3(11), 900-911. doi: 10.1038/nri1226 PMID: 14668806
  61. Valentino, L.; Pierre, J. JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem. Pharmacol., 2006, 71(6), 713-721. doi: 10.1016/j.bcp.2005.12.017 PMID: 16426581
  62. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; Scott, M.A.; Erber, W.N.; Green, A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365(9464), 1054-1061. doi: 10.1016/S0140-6736(05)71142-9 PMID: 15781101
  63. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med., 2005, 352(17), 1779-1790. doi: 10.1056/NEJMoa051113 PMID: 15858187
  64. Vinayal, P.A.; G, B.D.; Qingjie, L.; L, J.W.; Harold, M.; Guifen, Z.; Kurt, Z. Carbazole and carboline kinase inhibitors. WO Patent 080474, 2010.
  65. Merry, C.; Fu, K.; Wang, J.; Yeh, I.J.; Zhang, Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle, 2010, 9(2), 279-283. doi: 10.4161/cc.9.2.10445 PMID: 20023404
  66. Ma, C.X.; Janetka, J.W.; Piwnica-Worms, H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med., 2011, 17(2), 88-96. doi: 10.1016/j.molmed.2010.10.009 PMID: 21087899
  67. Goto, H.; Izawa, I.; Li, P.; Inagaki, M. Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci., 2012, 103(7), 1195-1200. doi: 10.1111/j.1349-7006.2012.02280.x PMID: 22435685
  68. Shumaila, A.M.; Puranik, V.G.; Kusurkar, R.S. Diastereoselective synthesis of tetrasubstituted-octahydro-3, 6-diazacarbazoles and tetrasubstituted-3, 6-diazacarbazoles via double Pictet–Spengler reaction. Tetrahedron Lett., 2011, 52(21), 2661-2663.
  69. Gazzard, L.; Appleton, B.; Chapman, K.; Chen, H.; Clark, K.; Drobnick, J.; Goodacre, S.; Halladay, J.; Lyssikatos, J.; Schmidt, S.; Sideris, S.; Wiesmann, C.; Williams, K.; Wu, P.; Yen, I.; Malek, S. Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. Bioorg. Med. Chem. Lett., 2014, 24(24), 5704-5709. doi: 10.1016/j.bmcl.2014.10.063 PMID: 25453805
  70. Uckun, F.M.; Tibbles, H.E.; Vassilev, A.O. Bruton’s tyrosine kinase as a new therapeutic target. Anticancer. Agents Med. Chem., 2007, 7(6), 624-632. doi: 10.2174/187152007784111331 PMID: 18045057
  71. Mohamed, A.J.; Nore, B.F.; Christensson, B.; Smith, C.I. Signalling of Bruton’s tyrosine kinase, Btk. Scand. J. Immunol., 1999, 49(2), 113-118. doi: 10.1046/j.1365-3083.1999.00504.x PMID: 10075013
  72. Buggy, J.J.; Elias, L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int. Rev. Immunol., 2012, 31(2), 119-132. doi: 10.3109/08830185.2012.664797 PMID: 22449073
  73. Kim, H.O. Development of BTK inhibitors for the treatment of B-cell malignancies. Arch. Pharm. Res., 2019, 42(2), 171-181. doi: 10.1007/s12272-019-01124-1 PMID: 30706214
  74. Gayko, U.; Fung, M.; Clow, F.; Sun, S.; Faust, E.; Price, S.; James, D.; Doyle, M.; Bari, S.; Zhuang, S.H. Development of the Bruton’s tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann. N. Y. Acad. Sci., 2015, 1358(1), 82-94. doi: 10.1111/nyas.12878 PMID: 26348626
  75. Lee, C.S.; Rattu, M.A.; Kim, S.S. A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib. J. Oncol. Pharm. Pract., 2016, 22(1), 92-104. doi: 10.1177/1078155214561281 PMID: 25425007
  76. Jian, L.; Joseph, K.; Ronald, K.; Xiaolei, G.; Babu, B.S.; Younong, Y.; Hao, W.; Shilan, L.; Chundao, Y. Azacarbazole BTK inhibitors. WO Patent 164284, 2016.
  77. Chunjian, L.; James, L. Carboline carboxamide compounds useful as kinase inhibitors. WO Patent 159857, 2011.
  78. Hunter, W.S. Tricyclic atropisomer compounds. WO 2016/065222, 2016.
  79. Belkina, A.C.; Denis, G.V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer, 2012, 12(7), 465-477. doi: 10.1038/nrc3256 PMID: 22722403
  80. Ran, X.; Zhao, Y.; Liu, L.; Bai, L.; Yang, C.Y.; Zhou, B.; Meagher, J.L.; Chinnaswamy, K.; Stuckey, J.A.; Wang, S. Structure-based design of γ-carboline analogues as potent and specific bet bromodomain inhibitors. J. Med. Chem., 2015, 58(12), 4927-4939. doi: 10.1021/acs.jmedchem.5b00613 PMID: 26080064
  81. Fung, J.J.; Kosaka, A.; Shan, X.; Danet-Desnoyers, G.; Gormally, M.; Owen, K. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. eLife, 2015, 4, e08997. doi: 10.7554/eLife.08997 PMID: 26327698
  82. Asangani, I.A.; Dommeti, V.L.; Wang, X.; Malik, R.; Cieslik, M.; Yang, R.; Escara-Wilke, J.; Wilder-Romans, K.; Dhanireddy, S.; Engelke, C.; Iyer, M.K.; Jing, X.; Wu, Y.M.; Cao, X.; Qin, Z.S.; Wang, S.; Feng, F.Y.; Chinnaiyan, A.M. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 2014, 510(7504), 278-282. doi: 10.1038/nature13229 PMID: 24759320
  83. Stathis, A.; Quesnel, B.; Amorim, S.; Thieblemont, C.; Zucca, E.; Raffoux, E.; Dombret, H.; Peng, Y.; Palumbo, A.; Vey, N.; Thomas, X.; Michallet, M.; Gomez-Roca, C.; Recher, C.; Karlin, L.; Yee, K.; Rezai, K.; Preudhomme, C.; Facon, T.; Herait, P. 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. Eur. J. Cancer, 2014, 50, 196. doi: 10.1016/S0959-8049(14)70726-9
  84. Vázquez, R.; Riveiro, M.E.; Astorgues-Xerri, L.; Odore, E.; Rezai, K.; Erba, E.; Panini, N.; Rinaldi, A.; Kwee, I.; Beltrame, L.; Bekradda, M.; Cvitkovic, E.; Bertoni, F.; Frapolli, R.; D’Incalci, M. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget, 2017, 8(5), 7598-7613. doi: 10.18632/oncotarget.13814 PMID: 27935867
  85. A, Q.C.; S, H.L.; D, H.M. Tricyclic compounds as anticancer agents. WO Patent 183114, 2016.
  86. Norris Derek, J.; Wayne, V. Tricyclic compounds as anticancer agents. WO Patent 183118, 2016.
  87. Jijun, L. Tricyclic compound for bromodomain-containing protein inhibitor and preparation, pharmaceutical composition, and application thereof. WO Patent 133681, 2017.
  88. Shankaraiah, N.; Jadala, C.; Nekkanti, S.; Senwar, K.R.; Nagesh, N.; Shrivastava, S.; Naidu, V.G.M.; Sathish, M.; Kamal, A. Design and synthesis of C3-tethered 1,2,3-triazolo-β-carboline derivatives: Anticancer activity, DNA-binding ability, viscosity and molecular modeling studies. Bioorg. Chem., 2016, 64, 42-50. doi: 10.1016/j.bioorg.2015.11.005 PMID: 26657602
  89. Sheng, J.; Gan, J.; Huang, Z. Structure-based DNA-targeting strategies with small molecule ligands for drug discovery. Med. Res. Rev., 2013, 33(5), 1119-1173. doi: 10.1002/med.21278 PMID: 23633219
  90. Delgado, J.L.; Hsieh, C.M.; Chan, N.L.; Hiasa, H. Topoisomerases as anticancer targets. Biochem. J., 2018, 475(2), 373-398. doi: 10.1042/BCJ20160583 PMID: 29363591
  91. Deveau, A.M.; Labroli, M.A.; Dieckhaus, C.M.; Barthen, M.T.; Smith, K.S.; Macdonald, T.L. The synthesis of amino-acid functionalized β-Carbolines as topoisomerase II inhibitors. Bioorg. Med. Chem. Lett., 2001, 11(10), 1251-1255. doi: 10.1016/S0960-894X(01)00136-6 PMID: 11392530
  92. Zhao, M.; Bi, L.; Wang, W.; Wang, C.; Baudy-Floc’h, M.; Ju, J.; Peng, S. Synthesis and cytotoxic activities of β-carboline amino acid ester conjugates. Bioorg. Med. Chem., 2006, 14(20), 6998-7010. doi: 10.1016/j.bmc.2006.06.021 PMID: 16806943
  93. Chaniyara, R.; Tala, S.; Chen, C.W.; Zang, X.; Kakadiya, R.; Lin, L.F.; Chen, C.H.; Chien, S.I.; Chou, T.C.; Tsai, T.H.; Lee, T.C.; Shah, A.; Su, T.L. Novel antitumor indolizino6,7-bindoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition. J. Med. Chem., 2013, 56(4), 1544-1563. doi: 10.1021/jm301788a PMID: 23360284
  94. Chikamori, K.; Grozav, A.G.; Kozuki, T.; Grabowski, D.; Ganapathi, R.; Ganapathi, M.K. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr. Cancer Drug Targets, 2010, 10(7), 758-771. doi: 10.2174/156800910793605785 PMID: 20578986
  95. Christodoulou, M.S.; Zarate, M.; Ricci, F.; Damia, G.; Pieraccini, S.; Dapiaggi, F.; Sironi, M.; Lo Presti, L.; García-Argáez, A.N.; Dalla Via, L.; Passarella, D. 4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II. Eur. J. Med. Chem., 2016, 118, 79-89. doi: 10.1016/j.ejmech.2016.03.090 PMID: 27128175
  96. Kwon, H.B.; Park, C.; Jeon, K.H.; Lee, E.; Park, S.E.; Jun, K.Y.; Kadayat, T.M.; Thapa, P.; Karki, R.; Na, Y.; Park, M.S.; Rho, S.B.; Lee, E.S.; Kwon, Y. A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases. J. Med. Chem., 2015, 58(3), 1100-1122. doi: 10.1021/jm501023q PMID: 25603122
  97. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M.L.; Rehman, M.; Walther, T.C.; Olsen, J.V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 2009, 325(5942), 834-840. doi: 10.1126/science.1175371 PMID: 19608861
  98. Chan, A.M.; Fletcher, S. Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. RSC Med. Chem., 2021, 12(2), 178-196. doi: 10.1039/D0MD00286K PMID: 34046608
  99. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5(9), 769-784. doi: 10.1038/nrd2133 PMID: 16955068
  100. Li, W.; Sun, Z. Mechanism of action for HDAC inhibitors-insights from omics approaches. Int. J. Mol. Sci., 2019, 20(7), 1616. doi: 10.3390/ijms20071616 PMID: 30939743
  101. Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.I.; Yao, T.; Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M.; Tsuneyoshi, M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep., 2007, 18(4), 769-774. doi: 10.3892/or.18.4.769 PMID: 17786334
  102. Ling, Y.; Guo, J.; Yang, Q.; Zhu, P.; Miao, J.; Gao, W.; Peng, Y.; Yang, J.; Xu, K.; Xiong, B.; Liu, G.; Tao, J.; Luo, L.; Zhu, Q.; Zhang, Y. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells. Eur. J. Med. Chem., 2018, 144, 398-409. doi: 10.1016/j.ejmech.2017.12.061 PMID: 29288941
  103. Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem., 2012, 4(4), 505-524. doi: 10.4155/fmc.12.3 PMID: 22416777
  104. Zhang, H.; Shang, Y.P.; Chen, H.; Li, J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol. Res., 2017, 47(2), 149-159. doi: 10.1111/hepr.12757 PMID: 27457249
  105. Namballa, H.K.; Anchi, P.; Lakshmi Manasa, K.; Soni, J.P.; Godugu, C.; Shankaraiah, N.; Kamal, A. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies. Bioorg. Chem., 2021, 117, 105461. doi: 10.1016/j.bioorg.2021.105461 PMID: 34753060
  106. Hamilton, E.; Infante, J.R. Targeting CDK4/6 in patients with cancer. Cancer Treat. Rev., 2016, 45, 129-138. doi: 10.1016/j.ctrv.2016.03.002 PMID: 27017286
  107. Li, D.; Liu, W.; Huang, Y.; Liu, M.; Tian, C.; Lu, H.; Jia, H.; Xu, Z.; Ding, H.; Zhao, Q. Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer. Bioorg. Chem., 2022, 121, 105659. doi: 10.1016/j.bioorg.2022.105659 PMID: 35180487
  108. Venkataramana Reddy, P.O.; Hridhay, M.; Nikhil, K.; Khan, S.; Jha, P.N.; Shah, K.; Kumar, D. Synthesis and investigations into the anticancer and antibacterial activity studies of β-carboline chalcones and their bromide salts. Bioorg. Med. Chem. Lett., 2018, 28(8), 1278-1282. doi: 10.1016/j.bmcl.2018.03.033 PMID: 29573910
  109. Chen, J.; Liu, T.; Wu, R.; Lou, J.; Dong, X.; He, Q.; Yang, B.; Hu, Y. Design, synthesis, and biological evaluation of novel γ-carboline ketones as anticancer agents. Eur. J. Med. Chem., 2011, 46(4), 1343-1347. doi: 10.1016/j.ejmech.2011.01.057 PMID: 21342735
  110. Cao, R.; Guan, X.; Shi, B.; Chen, Z.; Ren, Z.; Peng, W.; Song, H. Design, synthesis and 3D-QSAR of β-carboline derivatives as potent antitumor agents. Eur. J. Med. Chem., 2010, 45(6), 2503-2515. doi: 10.1016/j.ejmech.2010.02.036 PMID: 20304536
  111. Shankaraiah, N.; Nekkanti, S.; Chudasama, K.J.; Senwar, K.R.; Sharma, P.; Jeengar, M.K.; Naidu, V.G.M.; Srinivasulu, V.; Srinivasulu, G.; Kamal, A. Design, synthesis and anticancer evaluation of tetrahydro-β-carboline-hydantoin hybrids. Bioorg. Med. Chem. Lett., 2014, 24(23), 5413-5417. doi: 10.1016/j.bmcl.2014.10.038 PMID: 25453799
  112. Kamal, A.; Srinivasulu, V.; Nayak, V.L.; Sathish, M.; Shankaraiah, N.; Bagul, C.; Reddy, N.V.S.; Rangaraj, N.; Nagesh, N. Design and synthesis of C3-pyrazole/chalcone-linked beta-carboline hybrids: antitopoisomerase I, DNA-interactive, and apoptosis-inducing anticancer agents. ChemMedChem, 2014, 9(9), 2084-2098. doi: 10.1002/cmdc.201300406 PMID: 24470122
  113. Jha, A.M.; Singh, A.C.; Bharti, M.K. Clastogenicity of carbazole in mouse bone marrow cells in vivo. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 2002, 521(1-2), 11-17. doi: 10.1016/S1383-5718(02)00210-3 PMID: 12437999
  114. Dang, Z.; Xu, S.; Zhang, H.; Gui, W.; Zhao, Y.; Duan, L.; Hu, W. In vitro and in vivo efficacies of carbazole aminoalcohols in the treatment of alveolar echinococcosis. Acta Trop., 2018, 185, 138-143. doi: 10.1016/j.actatropica.2018.05.007 PMID: 29746870
  115. Patel, O.P.S.; Mishra, A.; Maurya, R.; Saini, D.; Pandey, J.; Taneja, I.; Raju, K.S.R.; Kanojiya, S.; Shukla, S.K.; Srivastava, M.N.; Wahajuddin, M.; Tamrakar, A.K.; Srivastava, A.K.; Yadav, P.P. Naturally occurring carbazole alkaloids from Murraya koenigii as potential antidiabetic agents. J. Nat. Prod., 2016, 79(5), 1276-1284. doi: 10.1021/acs.jnatprod.5b00883 PMID: 27136692
  116. Ghobadian, R.; Esfandyari, R.; Nadri, H.; Moradi, A.; Mahdavi, M.; Akbarzadeh, T.; Khaleghzadeh-Ahangar, H.; Edraki, N.; Sharifzadeh, M.; Amini, M. Design, synthesis, in vivo and in vitro studies of 1,2,3,4-tetrahydro-9H-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors. Mol. Divers., 2020, 24(1), 211-223. doi: 10.1007/s11030-019-09943-6 PMID: 30927138

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers